In 2016, the Ministry of Health of the Russian Federation established a cluster for direct innovative development by creating a special federal centre – the Centre for Strategic Development, which collects and analyses information, compiles databases of competent specialists in each of our country’s 85 regions and across all sectors. The development of this cluster allowed us to move on to new organizational mechanisms — Veronika Skvortsova, Minister of Health of the Russian Federation.
The ‘Pharma 2030’ programme includes the most modern aspects: vaccines, biomedical cell products, gene therapy drugs, medical industry. <...> This is one of the most promising programmes. Both the sector and the businesses are waiting for it and fully support it — Alexey Martynov, President, Association of Biomedical Cellular Products Manufacturers.
Basically, today we have agreed that starting next year we will have a unified tool for financing drug research projects, which will allow us to give such subsidies upfront, so that we could pay advances to companies. <...> Together with RVC we are creating a venture capital fund to finance early development, risky development and long-term development. <...> We could consider financing part of the projects at early stages through venture capital instruments — Sergey Tsyb, First Deputy Minister of Industry and Trade of the Russian Federation .
If our smallest companies which are at pre-clinical research stages, at the early phases, somehow get the support from industrial companies, through acquisitions too, that would create more incentive to turn the inventions of our scientists into medicines — Alexey Repik, Chairman, Russian-Japanese Business Council; President, Delovaya Rossiya (Business Russia); Chairman of the Board, Group R-Pharm .
We are a big country; our logistics is complicated. We are talking about 5,000 patients. How do we build a centralized cell treatment centre for the patients? We need to understand that the fastest way is to help businesses that already have patients. Our government centres must help businesses to create such technologies. That is the only path towards practical implementation — Dmitry Morozov, General Director, BIOCAD.